SAN LUIS OBISPO, California – March 30, 2010 – FzioMed, Inc. announced today expansion of Oxiplex® Adhesion Barrier Gel for Spine Surgery in both Asia and South America. In late 2009, FzioMed obtained approval for the Oxiplex® brand in South Korea and Brazil, and the Company recently appointed additional distributors in both countries. Product training and launches are now underway.
“Oxiplex is the leading product of its kind in the world,” said John Krelle, President & Chief Executive Officer, “FzioMed is enjoying strong growth in international sales and we expect the new sales initiatives in Asia and South America to add to this positive trend.”
Oxiplex is an absorbable gel placed at sites of tissue injury in the epidural space during lumbar laminectomy, laminotomy and discectomy surgical procedures. Oxiplex is intended to act as a temporary barrier separating tissue surfaces to reduce pain, radiculopathy, lower extremity weakness, and the incidence and severity of postoperative adhesions.
Oxiplex has been used in more than 160,000 spine surgeries to date and FzioMed products are approved for sale in 67 countries outside the United States.
FzioMed is a privately held medical device company developing and commercializing absorbable, surgical biomaterials based on the company’s patented science. FzioMed’s polymer technology has uses in a variety of surgical specialties including orthopedics, spine, gynecology and general surgery.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.